UTHR Stock Cash Flow Statements

United Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

United Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-09-30

cash flows from operating activities:
net income	309,500,000	322,200,000	301,300,000	309,100,000	278,100,000	306,600,000	217,100,000	267,600,000	259,200,000	240,900,000	132,100,000	239,300,000	116,000,000	239,900,000	112,200,000	162,700,000	172,600,000	28,300,000	98,800,000	171,200,000	107,100,000	137,700,000	52,600,000	132,400,000	205,100,000	-494,600,000	106,500,000	172,900,000	244,500,000	276,300,000	-56,000,000	178,600,000	161,800,000	206,100,000	235,500,000	464,425,000	99,211,000	-16,641,000	-25,237,000	111,852,000	137,524,000	62,685,000	79,864,000	62,325,000	78,111,000	72,316,000	70,760,000	84,398,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	21,100,000	19,800,000	19,700,000	19,100,000	18,700,000	15,000,000	13,700,000	13,300,000	12,900,000	13,300,000	13,200,000	12,900,000	12,700,000	12,500,000	12,600,000	12,400,000	12,400,000	12,500,000	13,100,000	11,800,000	12,600,000	12,400,000	12,500,000	12,700,000	10,400,000	10,300,000	9,400,000	8,100,000	7,900,000	7,700,000	7,700,000	7,900,000	8,200,000	7,900,000	7,700,000	8,248,000	8,382,000	8,330,000	8,107,000	7,641,000	7,565,000	7,661,000	7,680,000	8,165,000	6,915,000	6,292,000	6,648,000	4,991,000
share-based compensation expense	37,800,000	31,800,000	27,000,000	41,700,000	49,700,000	25,600,000	16,600,000	21,100,000			64,800,000	-2,400,000			44,700,000	24,600,000	29,100,000	40,100,000	93,700,000	-12,500,000	51,800,000	30,800,000	29,500,000			29,200,000										-118,928,000	47,284,000	234,530,000				74,385,000	32,986,000	35,213,000	31,145,000
impairment of property, plant, and equipment
other	4,600,000	9,400,000	-2,600,000	-5,700,000	-5,500,000	-10,500,000	-5,000,000	-1,800,000	-3,900,000	5,800,000	7,900,000	10,000,000	46,800,000	-12,200,000	37,900,000	31,000,000	5,500,000	-8,500,000	-40,200,000	7,100,000	8,900,000	-22,800,000	-1,800,000	9,100,000	-43,700,000	6,700,000							1,400,000								199,000
changes in operating assets and liabilities:
accounts receivable	-57,300,000	-42,700,000	62,500,000	-51,100,000	16,500,000	-28,300,000	-20,300,000	14,000,000	-138,100,000	85,900,000	11,300,000	-58,300,000	-2,800,000	28,100,000	14,100,000	-39,300,000	-32,400,000	16,300,000	-5,100,000	19,700,000	-22,300,000	1,700,000	32,200,000	-2,500,000	-21,300,000	16,000,000	36,100,000	-40,200,000	86,000,000			26,500,000						6,134,000						15,030,000			63,000
inventories	-7,400,000	-11,200,000	-11,600,000	-11,300,000	-14,700,000	-9,300,000	-7,000,000	-3,100,000	-1,000,000	-2,500,000	-13,900,000	-600,000	-4,600,000	5,700,000	-100,000	-8,200,000	3,000,000	-2,200,000	-800,000	500,000	4,500,000	6,100,000	2,400,000	6,100,000	2,700,000	1,700,000	-4,700,000	2,500,000	6,400,000																		575,000
accounts payable and accrued expenses	46,100,000	-2,600,000	-18,000,000	33,000,000	25,800,000	1,900,000	-23,100,000	39,400,000	38,000,000	2,800,000	9,100,000	22,300,000	23,900,000	-10,800,000	-34,500,000	19,800,000	27,200,000	-25,000,000	10,700,000	25,300,000	21,400,000	-18,800,000	-11,400,000	-1,900,000			-18,000,000	17,900,000	22,000,000	17,100,000			-5,900,000	19,300,000	500,000	2,499,000	18,579,000	4,747,000	15,838,000	8,293,000	11,724,000
other assets and liabilities	-184,400,000	134,500,000	-37,100,000	42,400,000	-136,400,000	75,500,000	-41,300,000	-4,300,000	-78,200,000	41,000,000	-94,300,000	29,300,000	-130,500,000	44,900,000	-12,600,000	-18,600,000	-71,500,000	-10,200,000	-44,000,000	18,900,000	-20,000,000	61,900,000	-11,500,000	-4,800,000			4,900,000	100,000	10,100,000			53,800,000			37,400,000
net cash from operating activities	191,700,000	461,200,000	341,200,000	377,200,000	232,200,000	376,500,000	150,700,000	346,200,000	106,300,000	374,800,000	128,200,000	258,600,000	127,000,000	288,700,000	174,600,000	185,600,000	148,200,000	89,800,000	126,200,000	250,900,000	164,000,000	214,600,000	102,500,000	185,400,000			204,500,000	179,800,000	275,700,000	258,500,000	70,700,000	230,800,000	228,700,000	125,700,000	125,800,000	207,313,000	40,982,000	108,951,000	208,537,000	-54,480,000	110,597,000	139,300,000	83,848,000	97,698,000	93,448,000	87,386,000	37,585,000	80,678,000
capex	-62,200,000	-74,900,000	-86,700,000	-76,500,000	-45,100,000	-38,200,000	-78,700,000	-65,700,000	-44,700,000	-41,300,000	-39,500,000	-68,800,000	-17,000,000	-13,500,000	-70,600,000	-23,300,000	-16,300,000	-10,600,000	-12,300,000	-15,800,000	-18,200,000	-13,000,000	-24,700,000	-13,600,000			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
free cash flows	129,500,000	386,300,000	254,500,000	300,700,000	187,100,000	338,300,000	72,000,000	280,500,000	61,600,000	333,500,000	88,700,000	189,800,000	110,000,000	275,200,000	104,000,000	162,300,000	131,900,000	79,200,000	113,900,000	235,100,000	145,800,000	201,600,000	77,800,000	171,800,000			204,500,000	179,800,000	275,700,000	258,500,000	70,700,000	230,800,000	228,700,000	125,700,000	125,800,000	207,313,000	40,982,000	108,951,000	208,537,000	-54,480,000	110,597,000	139,300,000	83,848,000	97,698,000	93,448,000	87,386,000	37,585,000	80,678,000
cash flows from investing activities:
purchases of property, plant, and equipment	-62,200,000	-74,900,000	-86,700,000	-76,500,000	-45,100,000	-38,200,000	-78,700,000	-65,700,000	-44,700,000	-41,300,000	-39,500,000	-68,800,000	-17,000,000	-13,500,000	-70,600,000	-23,300,000	-16,300,000	-10,600,000	-12,300,000	-15,800,000	-18,200,000	-13,000,000
deposits	-600,000	-9,200,000	-6,000,000	-17,800,000	-400,000	-4,300,000	-8,700,000	-10,600,000
purchases of available-for-sale debt securities	-1,806,900,000	-692,300,000	-478,500,000	-407,800,000	-230,500,000	-529,300,000	-308,000,000	-644,800,000	-672,000,000	-889,500,000
maturities of available-for-sale debt securities	304,200,000	611,700,000	478,000,000	387,200,000	196,500,000	475,300,000	526,700,000	407,700,000	493,200,000	709,700,000
sales of available-for-sale debt securities			0	0	0	831,800,000
purchase of investment in privately-held company				0							0
net cash from investing activities	-299,900,000	-164,700,000	-123,200,000	-114,900,000	-80,000,000	735,300,000	42,100,000	-313,400,000	-227,200,000	-221,100,000	-189,300,000	-94,000,000	-169,000,000	-359,200,000	-195,800,000	-235,900,000	-48,900,000	-6,300,000	-63,800,000	-271,700,000	-375,400,000	-27,600,000	66,200,000	-298,700,000									20,100,000	7,700,000	12,000,000	347,648,000	31,067,000	68,455,000	97,949,000	82,178,000	106,379,000		26,569,000	10,635,000
cash flows from financing activities:
payments to repurchase common stock			0	0	0	-1,000,000,000
proceeds from line of credit											0	0	0	800,000,000									0	0	0	800,000,000	0			0									65,000,000
repayment of line of credit	-400,000,000	-100,000,000	-100,000,000	-100,000,000	-100,000,000	-100,000,000					0	0	0	-800,000,000					0	0	0	-50,000,000	-150,000,000
excise tax paid on net share repurchase
payments of debt issuance costs			0	0	0	-2,700,000	0	0	0	-2,700,000	0	0	0	-7,500,000									0	0
proceeds from the exercise of stock options	18,100,000	16,600,000	25,700,000	32,500,000	52,100,000	42,200,000	7,300,000	4,600,000	24,700,000	61,400,000	55,500,000	4,700,000	23,900,000	4,300,000	7,700,000	14,000,000	10,800,000	17,500,000	7,900,000	3,500,000	21,700,000	700,000	0	0	1,100,000	8,800,000	600,000	5,700,000	9,200,000	1,600,000	3,600,000	33,000,000	1,200,000	2,400,000	2,600,000	8,574,000	14,313,000	10,132,000	17,220,000	13,795,000	8,376,000	8,481,000	7,157,000	4,258,000	6,575,000	1,304,000	1,810,000	224,000
proceeds from the issuance of stock under espp	0	4,900,000	-100,000	3,800,000	0	3,900,000	0	3,200,000	0	3,400,000	0	2,600,000
rsus withheld for taxes	-200,000	-15,300,000	-300,000	-400,000	-100,000	-11,400,000	-100,000	-200,000	0	-13,500,000	0	-300,000	0	-11,100,000
net cash from financing activities	-198,600,000	-93,800,000	-74,700,000	-64,100,000	-48,000,000	-1,068,000,000	-92,800,000	7,600,000	24,700,000	48,600,000	55,500,000	7,000,000	23,900,000	-11,000,000	7,500,000	16,600,000	10,600,000	10,100,000	6,100,000	5,600,000	21,600,000	-50,200,000	-150,000,000	-48,300,000	400,000	809,100,000	2,400,000	-6,800,000	10,600,000	3,500,000	3,600,000	34,400,000												694,000			2,128,000	421,000
net increase in cash and cash equivalents	-306,800,000	202,700,000	143,300,000	198,200,000	104,200,000	43,800,000	100,000,000	40,400,000	-96,200,000	202,300,000	-5,600,000	171,600,000	-18,100,000	-81,500,000	-13,700,000	-33,700,000	109,900,000	93,600,000	68,500,000	-15,200,000	-189,800,000	136,800,000	18,700,000	-161,600,000	90,700,000	121,400,000		-186,800,000	227,600,000			99,600,000	115,500,000	-9,300,000	15,000,000			28,812,000			134,905,000	-21,320,000	81,424,000	108,096,000				22,863,000
cash and cash equivalents, beginning of period	0	1,697,200,000		0	0	1,207,700,000		0	0	961,200,000		0	0	894,800,000		0	0	738,700,000		0	0	738,400,000		0	0	669,200,000	0	0	705,100,000	0	0	1,023,000,000	0	0	831,800,000	0	0	397,697,000	5,369,000	0	278,889,000	0	0	154,030,000	0	0	162,676,000	0
cash and cash equivalents, end of period	-306,800,000	1,899,900,000		198,200,000	104,200,000	1,251,500,000		40,400,000	-96,200,000	1,163,500,000		171,600,000	-18,100,000	813,300,000		-33,700,000	109,900,000	832,300,000		-15,200,000	-189,800,000	875,200,000		-161,600,000	90,700,000	790,600,000	-89,900,000	-186,800,000	932,700,000	61,600,000	-116,700,000	1,122,600,000	115,500,000	-9,300,000	846,800,000	510,846,000	-172,150,000	426,509,000	238,245,000	-154,748,000	413,794,000	-21,320,000	81,424,000	262,126,000	106,412,000	347,000	156,666,000	22,863,000
supplemental cash flow information:
cash paid for interest	4,200,000	5,400,000	7,200,000	9,600,000	10,800,000	12,600,000	14,200,000	14,600,000	14,100,000	13,100,000	11,300,000	8,400,000	5,300,000	4,100,000	4,100,000	4,000,000	4,100,000	4,000,000	4,100,000	4,200,000	4,900,000	7,500,000	9,300,000	11,100,000	11,400,000	9,200,000	2,400,000	2,200,000	2,300,000	2,200,000	600,000	1,000,000	0	0	100,000	216,000	59,000	682,000	2,016,000	756,000	1,971,000	2,007,000	744,000	2,031,000	2,005,000	755,000	1,803,000	706,000
cash paid for income taxes	253,400,000	500,000	111,300,000	77,300,000	207,300,000	4,700,000	96,600,000	88,400,000			86,600,000	51,000,000			23,200,000	44,700,000			30,500,000	18,300,000			25,800,000	31,700,000	61,800,000	900,000	20,600,000	31,300,000	200,000	92,700,000			61,700,000	133,400,000	88,600,000	6,818,000	93,915,000	16,173,000	37,317,000	73,563,000	66,803,000	33,983,000	40,700,000	44,949,000	18,737,000	27,633,000	28,676,000	10,994,000
non-cash investing and financing activities:
non-cash additions to property, plant, and equipment	19,000,000	47,200,000	-1,400,000	5,700,000	-5,700,000	23,600,000	-16,400,000	2,100,000	14,300,000	18,400,000	700,000	1,200,000	6,400,000	6,200,000	-300,000	700,000	-1,800,000	5,100,000	-900,000	-2,500,000	1,500,000	5,400,000
measurement period adjustment to purchase price			0	-2,800,000	0	1,400,000
excise tax on net share repurchase			-800,000	-600,000	-500,000	6,900,000
receivable from maturity of available-for-sale debt securities							-39,000,000
impairment of investment in privately-held company														1,700,000
impairments of property, plant, and equipment							0				4,200,000				1,000,000	1,200,000	0	17,000,000
realized gain on sale of investment in privately-held company
realized gain on sale of equity securities											0				-700,000	0	0	-91,900,000
sales of investments in equity securities											0				2,600,000	0	0	108,900,000	0	13,100,000	1,000,000	13,200,000
sale of investment in privately-held company
proceeds from note receivable
purchases of investments in privately-held companies
acquisitions, net of cash acquired
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
impairments of investments in privately-held companies											0	0			0	0			0	3,500,000	0	5,600,000
intangible asset impairment charges															0	0	0	113,400,000						0
share-based compensation benefit										-12,400,000
proceeds from sale of property, plant, and equipment																			0
purchases of available-for-sale investments												-270,000,000	-530,500,000	-477,600,000		-529,000,000	-310,400,000	-559,000,000	-610,000,000	-604,500,000	-615,100,000	-479,200,000	-296,800,000	-455,700,000
maturities of available-for-sale investments												242,500,000	378,500,000	131,900,000		308,600,000	240,500,000	454,400,000											70,000,000
sales of available-for-sale investments																0
share-based compensation (benefit) expense														-21,100,000
proceeds from the issuance of stock under employee stock purchase plan														3,300,000	0	2,800,000	0	2,800,000	0	2,200,000	0	2,500,000	0	1,900,000	0	2,200,000	1,800,000	0	2,100,000
cash paid (received) for income taxes														400,000
sales/maturities of held-to-maturity investments																							0	1,500,000	800,000	37,400,000
decrease in cash due to deconsolidation of variable interest entity																							0
restricted stock units withheld for taxes															-200,000	-200,000	-200,000	-10,200,000	-100,000	-100,000	-100,000	-3,400,000	0	-200,000
cash received for income taxes																		-1,600,000
asset impairment charges																							8,800,000
purchases of held-to-maturity and other investments
acquisition, net of cash acquired
deconsolidation of variable interest entity
sales/maturities of available-for-sale investments																				333,100,000	256,900,000	451,400,000	361,600,000	188,200,000	116,400,000	313,900,000	49,000,000
purchase of investments in privately-held companies																								-1,000,000

cash (received) paid for income taxes																						-8,700,000
adjustments to reconcile net income to net cash (used in)/provided by operating activities:
purchases of property, plant and equipment																							-24,700,000	-13,600,000
proceeds from sale of property, plant and equipment
consolidation of variable interest entity																														0
effect of exchange rate changes on cash and cash equivalents																														-200,000					400,000												268,000	-274,000
cash paid for settlement of loss contingency
non-cash additions to property, plant and equipment																							50,600,000	-100,000	-1,800,000	5,800,000	800,000	3,500,000	13,900,000	700,000	500,000	6,500,000	-200,000	100,000	3,300,000	1,026,000	1,047,000	355,000
loss contingency
maturities of held-to-maturity investments																											25,400,000	800,000	26,800,000	26,500,000	5,300,000	20,800,000	29,200,000	28,600,000	21,000,000	59,606,000	76,121,000	96,697,000	116,669,000	140,039,000	235,125,000	109,764,000	112,888,000	126,623,000	110,928,000	151,345,000	177,714,000	213,022,000
purchase of an investment in a privately-held company
impairment of cost method investments
estimated loss contingency																														900,000
excess tax benefits from share-based compensation																																	1,100,000	1,400,000	2,100,000	7,887,000	14,767,000	8,725,000	9,143,000	8,434,000	5,606,000	3,173,000	1,672,000	962,000	1,400,000	366,000	318,000	197,000
purchase of investments held at cost
purchase of investments under the equity method
intangible assets acquired
principal payments of debt
issuance of stock under employee stock purchase plan																														1,900,000	0	2,100,000	2,100,000	0	2,200,000	2,027,000	0	1,927,000	1,657,000	-62,000	1,734,000			1,378,000
issuance of common stock upon conversion of convertible notes																																	1,400,000	6,000,000	100,000	7,301,000	235,513,000	27,759,000
impairment of cost method investment
purchases of held-to-maturity investments and other
gain on sale of intangible asset
purchases of held-to-maturity investments
purchase of investments under the cost method
amortization of debt discount and debt issue costs																																		0	100,000	455,000	3,048,000	2,005,000	3,436,000	3,267,000	3,265,000	3,172,000	3,157,000	3,083,000	2,997,000	2,981,000	2,924,000	4,627,000
amortization of discount or premium on investments																																		100,000	200,000	432,000	440,000	994,000	1,207,000	1,384,000	1,604,000	1,028,000	1,032,000	1,006,000	970,000	1,199,000	1,134,000	969,000
payments on the line of credit
supplemental schedule of cash flow information:
non-cash investing activities and financing activities:
net decrease in cash and cash equivalents
current and deferred income tax expense																																							-10,596,000	61,181,000	75,692,000	38,494,000	38,655,000	28,510,000	30,382,000	30,974,000	33,176,000
other assets																																							3,324,000	231,000	500,000
other liabilities
non-cash investing activities:
non-cash investing activity: non-cash additions to property, plant and equipment																																							-1,131,000	-2,478,000	6,907,000	369,000	1,886,000	799,000		-3,179,000	9,083,000
benefit from inventory obsolescence																																								994,000	459,000				-235,000	1,343,000	347,000
cost-method investments
insurance proceeds receivable
investments in privately-owned companies
equity loss in affiliate and other																																											1,002,000	311,000	-33,000	8,187,000	26,000	-5,829,000
prepaid expenses																																											1,313,000	4,561,000
accounts payable																																												119,000				149,000
accrued expenses																																													20,561,000	8,629,000	915,000
net used in financing activities
expense associated with outstanding license fees
acquisitions
acquisitions—non cash consideration
provisions for inventory obsolescence
deferred tax expense																																																19,225,000
share-based compensation
sales of trading investments
restrictions on cash
provisions for bad debt and inventory obsolescence
redemptions of trading investments

We provide you with 20 years of cash flow statements for United Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of United Therapeutics stock. Explore the full financial landscape of United Therapeutics stock with our expertly curated income statements.

The information provided in this report about United Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.